China adds injectable semaglutide to its 2026 essential medicines list

China’s official 2026 National Essential Medicines List now includes injectable semaglutide. The National Health Commission catalog lists semaglutide as item 325, immediately after liraglutide, expanding the GLP-1 class represented in the national list.

What the official documents say

The Chinese government announcement says the updated list contains 794 medicines, adds 68 pharmaceutical and biological products compared with the 2018 edition, and takes effect in September 2026. Officials estimated that listed medicines account for about 71% of drug volume used by public medical institutions.

The catalog specifies semaglutide injection at 1.34 mg/mL in 1.5 mL and 3 mL prefilled pens. Liraglutide is item 324, making semaglutide the second GLP-1 receptor agonist shown in this section of the national list.

What essential-medicine status means

• The list guides procurement and prescribing across Chinese medical institutions.
• China defines essential medicines around basic health needs, reliable supply, equitable access, and comparative cost-effectiveness.
• The government says all newly added medicines were already included in the national reimbursement drug list.
• The update is designed in part to expand options for prevalent conditions including diabetes and hypertension.

What the announcement does not establish

• It does not guarantee that every facility will have immediate stock.
• It does not publish procurement volumes or a new negotiated price for semaglutide.
• It does not distinguish brand-name from future generic supply in the catalog entry.
• It does not by itself show how quickly patient access will change after the September effective date.

The defensible conclusion is policy-specific: China has formally added injectable semaglutide to the 2026 essential-medicines framework. The consequences for pricing, generic competition, and global supply will require later procurement and utilization data.